← All stocks

RECURSION PHARMACEUTICALS, INC.

RXRX Scheduled selling only

CIK 0001601830 #2125 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$179.02K

$179.02K on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 2 sales

Net

−$179.02K

$0.00 against sales at will

By person

14 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Borgeson Blake

Director

—

$100.20K (1) scheduled

−$100.20K

6,158,287

1.15%

$21.66M

−13.5%

Khan Najat

CEO and President

—

$78.82K (1) scheduled

−$78.82K

2,072,890

0.3872%

$7.29M

+317.1%

Secora Michael

Chief Financial Officer

—

1,487,694

0.2779%

$5.23M

+6.1%

Li Dean Y

Director

—

1,473,329

0.2752%

$5.18M

+9.6%

Taylor Ben R

Chief Financial Officer

—

1,071,462

0.2001%

$3.77M

+115.8%

Hallett David

Chief Scientific Officer

—

1,043,837

0.1950%

$3.67M

+75.7%

Gibson Christopher

Director

—

883,735

0.1651%

$3.11M

+15.9%

Marriott Tina

President and COO

—

506,852

0.0947%

$1.78M

−2.7%

Dar Zavain

Director

—

240,764

0.0450%

$846.91K

+131.5%

Mauro David J

Chief Medical Officer

—

225,429

0.0421%

$792.97K

−1.8%

Michor Franziska

Director

—

215,477

0.0403%

$757.96K

—

HERSHBERG ROBERT

Director

—

162,156

0.0303%

$570.40K

+213.6%

Sun Elaine D

Director

—

135,981

0.0254%

$478.33K

—

Bumpus Namandje

Director

—

127,632

0.0238%

$448.96K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 6

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 2

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 137,569

History held since 19 Apr 2021